17 results about "Prognosis Marker" patented technology

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

Disclosed is an isoform of hexokinase 1 (HK1), namely hexokinase 1b (HK1b), for use as a prognosis marker and as a specific target for use in treatment of cancer.

The invention discloses a prognosis marker and a dynamic prognosis prediction method for colorectal cancer liver metastasis. The method comprises the following steps: S1, acquiring clinical pathological characteristic data of a patient with colorectal cancer liver metastasis and a longitudinal laboratory marker measured during post-operation follow-up visit; s2, extracting a change trend of the longitudinal laboratory marker by utilizing multivariable function principal component analysis to obtain a principal component score; s3, training a random survival forest model by using the principal component score and the clinical pathological feature data to obtain a dynamic prediction model; s4, dynamically updating the score of the principal component based on a newly collected laboratory marker of postoperative follow-up visit of the patient, and outputting dynamic risk assessment results of the progression-free lifetime and the total lifetime of the patient through a dynamic prediction model; according to the method, the prediction model capable of dynamically evaluating the survival risk of the patient is constructed and updated by fusing the dynamic longitudinal laboratory marker and the static clinical pathological characteristics.

The application provides a molecular marker for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma and application thereof, and belongs to the technical field of biological detection. Through bioinformatics analysis methods such as multivariate statistical analysis, difference screening, single factor COX regression analysis and multi-factor COX regression analysis, the application obtains an adenine kinase 4 used for evaluating the prognosis marker of cervical squamous cell carcinoma and a brain sponge-shaped deformity 2 protein used for evaluating the prognosis biomarker of cervical adenocarcinoma. Based on the biomarkers of the application, a kit for evaluating cervical squamous cell carcinoma or adenocarcinoma is constructed, which is used for accurately evaluating the prognosis of cervical squamous cell carcinoma or adenocarcinoma.

The application discloses a liver cancer prognosis marker and application thereof, and the liver cancer prognosis marker comprises TXNRD1, HAO1, C1S, OPTN and SNX6. The application provides a group of liver cancer prognosis markers, and a liver cancer patient prognosis prediction model is constructed based on the liver cancer prognosis markers. The liver cancer prognosis markers are obtained through comprehensive gene expression levels, single cell analysis and spatial transcriptome analysis, and the diversity of the data set and the large sample quantity improve the reliability and universality of the liver cancer prognosis markers and the liver cancer patient prognosis prediction model.

The invention belongs to the technical field of biological medicine, and particularly relates to a biliary atresia differential diagnosis and prognosis marker and application thereof. The invention provides the application of the KRT17 expression level as a biliary atresia differential diagnosis and prognostic marker for the first time. KRT17 as a single marker has a relatively high diagnostic value (AUC = 0.880) for BA, the efficiency of KRT17 is superior to all conventional clinical liver function indexes, and when KRT17 is combined with alanine aminotransferase for use, the diagnostic accuracy can be further improved to AUC = 0.904, the KRT17 and CX3CL1 are optimally combined, and the AUC value is as high as 0.938. According to the technology, KRT17 is used as a novel biliary atresia differential diagnosis marker, the defects of an existing differential diagnosis system can be made up to a certain degree, the KRT17 is specifically and highly expressed in biliary atresia liver bile duct epithelial cells, normal control and disease control are not expressed, and therefore more accurate differential diagnosis can be provided clinically.

The application discloses application of TGM2 as a cervical cancer diagnosis, prognosis biomarker and therapeutic target. The application provides a new cervical cancer diagnosis and prognosis marker TGM2, which can clearly characterize the occurrence and development of cervical cancer; the marker presents specific high expression phenomenon in comparison with normal tissue in human clinical cervical cancer tissue; and the marker also presents high expression in human cervical cancer cell lines. Knocking down TGM2 can inhibit the proliferation and migration ability of cervical cancer cells; TGM2, as an enzyme, has high application potential as a diagnosis and treatment target. The application provides a new marker and target for the diagnosis, prognosis and treatment of cervical cancer, and can provide a new strategy and direction for the treatment of cervical cancer.

The application provides a lung adenocarcinoma prognosis marker and model, a lung adenocarcinoma prognosis model based on programmed cell death (PCD) related mRNA and lncRNA is constructed, and the biological function of the lncRNA model in lung adenocarcinoma is explored through bioinformatics analysis and experiments. The prognosis model covers all PCD pathways and various molecules, has a robust prognosis prediction accuracy, and can provide potential molecular targets for personalized treatment. The method of the application comprehensively constructs a lung adenocarcinoma diagnosis model suitable for Chinese population by using PCD related mRNA and lncRNA, enhances the recognition ability of tumor patient classification from multiple aspects, improves the accuracy and reliability of prognosis prediction, can provide strong support for promoting the personalized treatment strategy of lung adenocarcinoma patients, and is suitable for popularization and application.

The application relates to the technical field of melanoma prognosis, and provides a construction method and a verification method of a melanoma prognosis model based on a lactation gene methylation feature. The DNA methylation data of a cancer genome atlas database is taken as a training set, and the DNA methylation data of a gene expression comprehensive database is taken as a verification set, so that the lactation-related gene methylation feature prognosis marker model of melanoma constructed has good external applicability. A methylation site pair matrix is constructed through the relative methylation order relationship of the methylation sites, so that the batch effect between different data sets is effectively avoided, and excellent robustness and clinical applicability are achieved. The methylation sites corresponding to the lactation-related gene set are taken as anchor points to perform hierarchical clustering and differential methylation site screening, functional sites related to prognosis are screened out, the reliability of the constructed prognosis marker model is improved, and the accuracy of prognosis prediction is improved.

The invention provides application of novel burkholderia cepacia as a marker for tumor diagnosis, screening, prediction or prognosis. The invention provides a qualitative and quantitative detection method for detecting the Burkholderia cenocepacia bacteria in the glioma for the first time. On one hand, through co-culture with Burkholderia cenocepacia bacteria, the malignant phenotypic capabilities of proliferation, invasion and the like of glioma cells can be remarkably enhanced; more importantly, the abundance value of the 16S rRNA gene of the Burkholderia cenocepacia bacteria can be used as a molecular marker for prognosis evaluation of the glioma and a target spot for treatment of the glioma. A new thought is provided for diagnosis of glioma, and important clinical value is achieved.

The invention discloses application of secretory LAMP1 as a non-small cell lung cancer immunotherapy curative effect and prognostic marker and an evaluation system, and relates to the technical field of biological medicine. According to the invention, sLAMP1 in serum is taken as a core biomarker, so that the curative effect and prognosis of ICB treatment of NSCLC patients can be effectively predicted. Meanwhile, a multi-dimensional prognosis evaluation system integrating sLAMP1 concentration, ECOG score, pathological subtype, gender, smoking state, age and other clinical pathological characteristics is constructed, and accurate prediction of one-year and three-year progression-free lifetime of the patient is realized. The system predicts that the AUC of PFS reaches up to 0.94 within 12 months, is easy to popularize in a standardized manner based on a mature ELISA platform, can assist clinicians in early screening of potential benefit crowds, identification of true and false progresses and timely adjustment of treatment strategies, can remarkably improve the precise whole-course management level of NSCLC immunotherapy, and has important clinical transformation value.

The invention discloses a prognostic marker for bladder cancer and application of the prognostic marker. The prognostic marker for the bladder cancer comprises CD14T, CD68S, CD163T and S100A12S; wherein the CD14T and the CD163T respectively refer to CD14 and CD163 expressed in a bladder cancer tumor region, and the CD68S and the S100A12S respectively refer to CD68 and S100A12 expressed in a bladder cancer matrix region. The bladder cancer prognosis marker provided by the invention can be used for constructing a bladder cancer prognosis prediction model, and multi-queue verification proves that the model has a strong prediction capability on the postoperative survival condition of a BLC patient and is beneficial to postoperative risk assessment and clinical decision of the BLC patient.

The application discloses a method for screening a triple-negative breast cancer prognosis gene marker, uses gene expression data of triple-negative breast cancer, obtains genes interacting with a cell proliferation marker, and screens prognosis-related genes by means of single-factor Cox regression, and the application uses a Cox regression method with minimum maximum concave penalty to construct a prognosis risk assessment model, and obtains a prognosis gene marker and a prognosis assessment method capable of predicting and assessing the risk of triple-negative breast cancer. The application proposes a prognosis marker gene identification technology for triple-negative breast cancer which is a high-heterogeneity disease, and the technology can be applied and popularized in clinical treatment.

The invention discloses an application of an NDUFA4L2 gene as a drug target for screening and treating neuroblastoma, and particularly relates to an application of the NDUFA4L2 gene as a drug target for screening and treating neuroblastoma, or as a prognostic marker of neuroblastoma, or as an indication marker of differentiation degree of neuroblastoma. The invention finds that NDUFA4L2 is remarkably high in expression in ganglion neuroma with the highest differentiation degree and is remarkably low in expression in neuroblastoma with the lowest differentiation degree. Prognostic analysis on NDUFA4L2 shows that high expression of NDUFA4L2 is related to better overall survival and event-free survival. According to the application, the differentiation promotion effect of NDUFA4L2 on neuroblastoma and the improvement effect of NDUFA4L2 on retinoic acid reactivity are respectively verified at in-vivo and in-vitro levels, tumor proliferation and metastasis of neuroblastoma can be indirectly inhibited, and a new biomarker for NB layered diagnosis and treatment and a new target for precise treatment are determined.

The invention discloses a hepatocellular carcinoma prognosis evaluation marker TKFC and application thereof, and belongs to the technical field of prognosis markers. By comparing tumor tissues of patients with different prognosis, the invention discovers that the HCC subtype with relatively strong invasiveness shows a systematic state imbalance, that is, the oxidative metabolism function represented by mitochondrial oxidative phosphorylation and tricarboxylic acid cycle is weakened, and the intracellular proliferation procedure related to chromatin remodeling and cell cycle progress is abnormally active. The state of low oxidative metabolism-high proliferation output may form the metabolism and epigenetic basis of malignant HCC. The low expression of the TKFC is obviously related to high-risk clinical pathological characteristics such as later tumor staging and higher occurrence rate of vascular invasion, and is an independent poor prognosis factor influencing the total lifetime of a patient, which indicates that the TKFC can be used as a prognosis biomarker of HCC.

The application provides application of NCBP1 as an auxiliary diagnosis and / or prognosis marker of diffuse large B-cell lymphoma (DLBCL), and belongs to the technical field of medicinal biology and molecular biology. The application first discovers that NCBP1 is highly expressed in DLBCL patients, the high expression of NCBP1 has a significant influence on the proliferation of DLBCL cells, and is related to poor prognosis; NCBP1 enhances the proliferation of DLBCL cells in a METTL3-dependent manner, NCBP1 enhances the m6A catalytic function of METTL3 by maintaining the stability of the oncogene METTL3 mRNA; the NCBP1 / METTL3 / m6A / c-MYC axis may be a mechanism for the development of DLBCL, which provides a new idea for molecular targeted therapy of DLBCL, enriches the understanding of the m6A modification system in DLBCL, and has important clinical application value.

The application discloses a method based on solid-phase glycoprotein T antigen glycopeptide enrichment and enzyme cutting analysis, which comprises the following steps: extracting protein from a sample; obtaining polypeptide through proteolysis; oxidizing galactose and N-acetyl galactose; fixing with hydrazide resin and cutting with PNGase F enzyme; treating with galactoside enzyme and performing mass spectrometry analysis. The method obtains three structures, T antigen glycopeptide of core 1, core 2 glycopeptide and core 8 glycopeptide. The T antigen glycopeptide and the core 2 glycopeptide are distinguished through mass spectrometry analysis, and the T antigen glycopeptide and the core 8 are distinguished through different glycosidases. The method can enrich and distinguish glycopeptides containing T antigens, core 2 and core 8, and has important significance for finding specific markers with T antigen modification in tumor tissues and body fluids, research on early diagnosis and prognosis markers of diseases and the like.